These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 28082118)

  • 1. Elevated Expression of Moesin in Muscular Dystrophies.
    Pines M; Levi O; Genin O; Lavy A; Angelini C; Allamand V; Halevy O
    Am J Pathol; 2017 Mar; 187(3):654-664. PubMed ID: 28082118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The involvement of collagen triple helix repeat containing 1 in muscular dystrophies.
    Spector I; Zilberstein Y; Lavy A; Genin O; Barzilai-Tutsch H; Bodanovsky A; Halevy O; Pines M
    Am J Pathol; 2013 Mar; 182(3):905-16. PubMed ID: 23274062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Halofuginone improves muscle-cell survival in muscular dystrophies.
    Bodanovsky A; Guttman N; Barzilai-Tutsch H; Genin O; Levy O; Pines M; Halevy O
    Biochim Biophys Acta; 2014 Jul; 1843(7):1339-47. PubMed ID: 24703880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of muscle fibrosis results in increases in both utrophin levels and the number of revertant myofibers in Duchenne muscular dystrophy.
    Levi O; Genin O; Angelini C; Halevy O; Pines M
    Oncotarget; 2015 Sep; 6(27):23249-60. PubMed ID: 26015394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.
    Turgeman T; Hagai Y; Huebner K; Jassal DS; Anderson JE; Genin O; Nagler A; Halevy O; Pines M
    Neuromuscul Disord; 2008 Nov; 18(11):857-68. PubMed ID: 18672370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.
    Halevy O; Genin O; Barzilai-Tutsch H; Pima Y; Levi O; Moshe I; Pines M
    Histol Histopathol; 2013 Feb; 28(2):211-26. PubMed ID: 23275304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Halofuginone and muscular dystrophy.
    Pines M; Halevy O
    Histol Histopathol; 2011 Jan; 26(1):135-46. PubMed ID: 21117034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxy group requirement for halofuginone-dependent inhibition of muscle fibrosis and improvement of histopathology in the mdx mouse model for Duchenne muscular dystrophy.
    Wellner G; Mordechay S; Evans P; Genin O; Pines M; Halevy O
    Histol Histopathol; 2019 Jul; 34(7):791-801. PubMed ID: 30628720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Effects of Halofuginone Enantiomers on Muscle Fibrosis and Histopathology in Duchenne Muscular Dystrophy.
    Mordechay S; Smullen S; Evans P; Genin O; Pines M; Halevy O
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse.
    Gibertini S; Zanotti S; Savadori P; Curcio M; Saredi S; Salerno F; Andreetta F; Bernasconi P; Mantegazza R; Mora M
    Cell Tissue Res; 2014 May; 356(2):427-43. PubMed ID: 24723230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study.
    Zhao Y; Haginoya K; Sun G; Dai H; Onuma A; Iinuma K
    J Pathol; 2003 Sep; 201(1):149-59. PubMed ID: 12950028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new model of experimental fibrosis in hindlimb skeletal muscle of adult mdx mouse mimicking muscular dystrophy.
    Desguerre I; Arnold L; Vignaud A; Cuvellier S; Yacoub-Youssef H; Gherardi RK; Chelly J; Chretien F; Mounier R; Ferry A; Chazaud B
    Muscle Nerve; 2012 Jun; 45(6):803-14. PubMed ID: 22581532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Halofuginone promotes satellite cell activation and survival in muscular dystrophies.
    Barzilai-Tutsch H; Bodanovsky A; Maimon H; Pines M; Halevy O
    Biochim Biophys Acta; 2016 Jan; 1862(1):1-11. PubMed ID: 26454207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma levels of tissue inhibitors of metalloproteinase-1 and their overexpression in muscle in human and mouse muscular dystrophy.
    Sun G; Haginoya K; Chiba Y; Uematsu M; Hino-Fukuyo N; Tanaka S; Onuma A; Iinuma K; Tsuchiya S
    J Neurol Sci; 2010 Oct; 297(1-2):19-28. PubMed ID: 20655547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eye muscle sparing by the muscular dystrophies: lessons to be learned?
    Andrade FH; Porter JD; Kaminski HJ
    Microsc Res Tech; 2000 Feb 1-15; 48(3-4):192-203. PubMed ID: 10679966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the normal content of sulfhydryl groups attributable to sparing from dystrophic pathology in dystrophin-deficient muscles?
    Niebrój-Dobosz I; Fidziańska A; Glinka Z; Hausmanowa-Petrusewicz I
    Folia Neuropathol; 2002; 40(3):143-50. PubMed ID: 12572920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice.
    Nevo Y; Halevy O; Genin O; Moshe I; Turgeman T; Harel M; Biton E; Reif S; Pines M
    Muscle Nerve; 2010 Aug; 42(2):218-29. PubMed ID: 20589893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
    Gutpell KM; Hrinivich WT; Hoffman LM
    PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-alpha 2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease?
    Taniguchi M; Kurahashi H; Noguchi S; Sese J; Okinaga T; Tsukahara T; Guicheney P; Ozono K; Nishino I; Morishita S; Toda T
    Biochem Biophys Res Commun; 2006 Apr; 342(2):489-502. PubMed ID: 16487936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.